• Possible link between depression and HHV-6 infection in childhood

    Serologic studies of several herpesviruses find that only HHV-6 may be linked to depression.

  • Reactivation of latent herpesviruses and HERVS after mild COVID-19

    Findings are accentuated in people with myalgic encephalomyelitis/chronic fatigue syndrome.

  • Virus specific T cell infusions show promise for preventing HHV-6B reactivation in transplant patients

    Review highlights the importance of cell mediated immunity and the limitations of antivirals, vaccines and immunoglobulin therapy for HHV-6, VZV and HSV.

  • Artesunate compares favorably to herpesvirus antivirals in suppressing HHV-6 and HHV-7

    Non-randomized study finds somewhat more potent reduction of virus in leucocytes over several months of treatment.

Newsletter | About Us | Contact Us | Donate | Repository

HHV-6 Foundation | HHV-6 Disease Information for Patients, Clinicians, and Researchers | Apply for a Grant Navigation
  • Home
  • About
    • Scientific Advisory Board
    • Staff
    • Contact Us
    • Donate
  • Patients
    • What Is HHV-6?
    • HHV-6A/B Testing
  • Research
    • Grants
    • Repository
      • Cart
      • Checkout
    • HHV-6A/B Testing
    • List of Genes & Proteins
    • Lab Protocols
    • Pictorial Atlas of HHV-6
    • HHV-6 Antivirals
    • Researcher FAQ
    • Newsletter
  • Home
  • About
    • Scientific Advisory Board
    • Staff
    • Contact Us
    • Donate
  • Patients
    • What Is HHV-6?
    • HHV-6A/B Testing
  • Research
    • Grants
    • Repository
      • Cart
      • Checkout
    • HHV-6A/B Testing
    • List of Genes & Proteins
    • Lab Protocols
    • Pictorial Atlas of HHV-6
    • HHV-6 Antivirals
    • Researcher FAQ
    • Newsletter

Latest Transplant Complications Articles

View Post

Substantial reduction in hippocampal volume found in pediatric hematopoietic stem cell transplant patients with HHV-6B reactivation

Surprisingly, the damage from HHV-6B infection often occurred in the absence of obvious neurological symptoms. Patients without HHV-6 reactivation had no reduction in volume.

View Post

Telomeric integration, excision and subsequent and transmission in people with inherited chromosomally integrated HHV-6B (iciHHV-6B)

Exploiting a hypervariable region of the HHV-6B genome, investigators achieve new insights about integration, excision, and genomic stability of iciHHV-6B

View Post

Significantly worse outcomes in critically ill hematology patients associated with HHV-6 infection.

Two reports associate detectable HHV-6 DNA in body fluids with increased risk of mortality in patients being treated for hematologic malignancies.

View Post

HHV-6 is the predominant reactivated virus, other than CMV, in post-transplant cyclophosphamide associated infections

Large, retrospective multi-institutional study of non-CMV herpesvirus infection in the HCT with cyclophosphamide prophylaxis finds higher rate of HHV-6 infection and associated higher mortality

View Post

Failure to detect iciHHV-6 leads to overtreatment in hematopoietic cell transplant recipients

Mistaking iciHHV-6 for a marked reactivation of naturally-acquired infection can lead to unnecessary diagnostic procedures and treatments, with adverse effects.

View Post

Foscarnet prophylaxis improved engraftment and survival in cord blood transplant patients

Six-month overall survival was 96% in the treated group compared to 72% in the untreated group.

View Post

In DRESS/DIHS, early treatment with high dose steroids may suppress HHV-6; late treatment may prolong viremia

High dose steroids given in the first week appears to prevent HHV-6 reactivation in DRESS/DIHS patients by suppressing T-cell activation and serum interleukin-2 receptor (sIL-2R) levels. In contrast, a late start of steroid therapy resulted in a persistently high viral load for at least three weeks.

View Post

CMV & HHV-6 cause severe complications in non-transplant acute leukemia patients

Herpesvirus co-infections, particularly HHV-6 and CMV, cause severe lymphopenia, pneumonia, and an increased risk of acquiring bacterial and fungal infections in non-transplant acute leukemia patients undergoing chemotherapy. 

View Post

Oral brincidofovir prophylaxis for CMV decreased incidence of HHV-6B viremia

Allogenic transplant patients who received prophylactic oral brincidofovir as part of a CMV trial had a reduced HHV-6B reactivation and lower viral loads.

View Post

Multiplex FilmArray Meningitis/Encephalitis assay is useful for diagnosing HHV-6 encephalitis

This multiplex qualitative test for cerebrospinal fluid helps physicians diagnose HHV-6 encephalitis quickly, but interpretation must take into account imaging, ciHHV-6 status and other markers.

View Post

New humanized mouse model mimics HHV-6B pathogenesis

Researchers led by Yasuko Mori of Kobe University in Japan have developed an animal model will be useful for studying the pathogenicity of HHV-6B in conditions such as acute GVHD and idiopathic pneumonia

View Post

Low sodium or SIADH may be an early indicator of HHV-6 encephalitis

A systematic review suggests that sodium imbalance is associated with HHV-6 encephalitis and syndrome of inappropriate diuretic hormone (SIADH) could serve as an early warning

View Post

Patients with iciHHV-6 have higher inflammatory cytokines and develop acute graft vs host disease a week earlier

Transplant patients born with chromosomally integrated HHV-6 have elevated levels of C-reactive protein and tumor necrosis factor receptor 1, both markers associated with increased risk of acute graft-versus-host disease.

View Post

European guidelines published for diagnosing, preventing, and managing HHV-6 disease

European guidelines recommend treating HHV-6 disease with either foscarnet or ganciclovir, in contrast to the Japanese guidelines that recommend foscarnet as first line treatment due to a lower mortality rate.

View Post

HHV-6B lung infection doubles the mortality rate of transplant patients with respiratory disease

Investigators at the Fred Hutchinson Cancer Research Center and University of Washington in Seattle found that HHV-6B in lung fluid of bone marrow transplant recipients with pneumonia is associated with a 2-fold increased risk of death. Importantly, HHV-6B positive patients who were treated with an antiviral had a 60% lower risk of death.

  • Page 2 of 7
  • ←
  • 1
  • 2
  • 3
  • ...
  • 7
  • →

Clinical News

  • Alzheimer’s Disease
  • Animal Models
  • Autoimmune Disease
  • Cancer
  • iciHHV-6
  • CNS Disease
  • COVID-19 / HHV-6 Reactivation
  • Drug Hypersensitivity
  • Encephalitis & Encephalopathy
  • Endocrine Conditions
  • Epilepsy and Seizures
  • Gastrointestinal
  • Genes
  • Heart Disease
  • Hematological Disorders
  • HIV/AIDS Progression
  • Immunity & Immunotherapy
  • Infertility & Miscarriage
  • Kidney Disease
  • Liver Disease
  • Lung Disease
  • Lymphadenopathy & Fever
  • ME/CFS
  • Multiple Sclerosis
  • Rash & Roseola
  • Transplant Complications
  • Treatments – Adoptive T cell
  • Treatments – Alternative
  • Treatments – Antiviral
  • Treatments – Immune Stimulant

About HHV-6

  • What Is HHV-6?
  • What is Inherited Chromosomally Integrated HHV-6
  • HHV-6 Repository of Reagents
  • HHV-6A/B Testing
  • HHV-6 Treatment

SUBSCRIBE TO OUR NEWSLETTER

ABOUT THE HHV-6 FOUNDATION

The HHV-6 Foundation in a non-profit entity founded to encourage scientific exchange between investigators and to provide pilot grants for promising scientific and clinical research on the under- appreciated viruses HHV-6A and HHV-6B.

The Foundation sponsors international conferences and supports scientists and clinicians seeking to clarify the role of the two HHV-6 viruses in disease. Since HHV-6A and HHV-6B can smolder in the brain and other organs without circulating in the peripheral blood or plasma, identifying chronic infection is a challenge.

Read More

HHV-6 Foundation | 1482 East Valley Road, Suite 619 | Santa Barbara, CA, 93108 | Toll Free: (888) 530-6726


Copyright ©2004-2022 HHV-6 FOUNDATION


WEB DESIGN AND DEVELOPMENT BY INSTYLE TECHNOLOGIES
  • Home
  • About
  • Conditions
  • Clinicians
  • Testing
  • Research
  • Repository
  • Patients
  • Treatment
  • News & Blog
  • Donate
  • Contact Us
  • Cart
  • Checkout
  • Privacy Policy
  • Terms of Use